Summary: We have studied the pharmacokinetics of epirubicin after its administration in sarcoma patients either as an i.v. bolus or as a 48-h infusion (5 courses each; 9 patients in total). Bolus injection was followed by a three exponential decay in plasma, with half-lives of 2.43 min, 1.95 h and 21.7 h; 48-h infusions were characterized by the very rapid establishment of a plasma plateau concentration followed by a biexponential decay after stopping the infusion. Pharmacokinetic parameters such as total plasma clearance, total volume of distribution, mean residence time and elimination half-life were similar, irrespective of the duration of the administration. In contrast, the relative amounts of the metabolites of epirubicin were reduced when the drug was administered over 48 h; in particular, the plasma levels of epirubicin glucuronide never exceeded those of epirubicin, which always occur after bolus injection. This may result from a lower availability of epirubicin for metabolism. These results now require validation in a larger group of patients using a cross-over design. © 1992 Kluwer Academic Publishers.
CITATION STYLE
Robert, J., & Bui, N. B. (1992). Original article: Pharmacokinetics and metabolism of epirubicin administered as I.V. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. Annals of Oncology, 3(8), 651–656. https://doi.org/10.1093/oxfordjournals.annonc.a058296
Mendeley helps you to discover research relevant for your work.